Pacific Health Summit

Perspectives from Industry
Tiered Pricing and Vaccine Access

February 6, 2012

As a follow-up to the 2011 Expert Interview with Ambassador Mark Dybul, NBR spoke with pharmaceutical leaders Mark Feinberg (Merck Vaccines at Merck & Co.), Suresh Jadhav (Serum Institute of India Ltd.), and Jean Stephénne (GlaxoSmithKline) about industry perspectives on the increasingly complex nature of vaccine development and the need for a revised tiered pricing structure that better addresses the needs of low- and middle-income countries.

What are the key challenges to improving access to vaccines in the 21st century? As a follow-up to the 2011 Expert Interview with Ambassador Mark Dybul, NBR spoke with pharmaceutical leaders Mark Feinberg (Merck Vaccines at Merck & Co.), Suresh Jadhav (Serum Institute of India Ltd.), and Jean Stephénne (GlaxoSmithKline) about industry perspectives on the increasingly complex nature of vaccine development and the need for a revised tiered pricing structure that better addresses the needs of low- and middle-income countries.